Deep sequencing analysis of variants resistant to the non‐structural 5<scp>A</scp> inhibitor daclatasvir in patients with genotype 1b hepatitis <scp>C</scp> virus infection

Abstract excerpt

AIM: Daclatasvir, a non-structural (NS)5A replication complex inhibitor, is a potent and promising direct antiviral agent (DAA) for hepatitis C virus (HCV), being most effective in genotype 1b infection. Although it is known that genotype 1b viruses with Y93H and/or L31M/V/F mutations have strong resistance to daclatasvir, it is not known whether there are some clinical background conditions that favor the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis C virus research
• Share to HIV/AIDS drug development and treatment
• Share to Trypanosoma species research and implications